Research Lab Results for cancer therapies
Cynthia Sears LaboratoryPrincipal Investigator:
Cynthia Sears, M.D.
Work in the Cynthia Sears Laboratory focuses on the bacterial contributions to the development ...of human colon cancer and the impact of the microbiome on other cancers and the therapy of cancer. The current work involves mouse and human studies to define how enterotoxigenic Bacteroides fragilis, pks+ Escherichia coli, Fusobacterium nucleatum, biofilms and the colonic microbiota induce chronic colonic inflammation and colon cancer. Prospective human studies of the microbiome and biofilms in screening colonoscopy are in progress as are studies to determine if and how the microbiome impacts the response of individuals with cancer to immunotherapy and other cancer therapies.Research Areas: epidemiology, AIDS, microbiome, colon cancer, enterotoxigenic Bacteroides fragilis, chronic colonic inflammation
Kathleen Gabrielson LaboratoryPrincipal Investigator:
Kathleen Gabrielson, D.V.M., Ph.D.
Molecular and Comparative Pathobiology
Research in the Kathleen Gabrielson Laboratory focuses on the signal transduction of cardiovasc...ular toxicities in vitro, in cardiomyocyte culture and in vivo using rodent models. Specifically, the research focuses on understanding the mechanisms of various cancer therapies that induce cardiac toxicities.Research Areas: cardiovascular toxicity, cancer, pathology, signal transduction
Currently, we are testing prevention strategies for these toxicities by studying the cardiac effects of the anthracycline doxorubicin (adriamycin) and the immunotherapeutic agent, Herceptin, anti-erbB2. We are focusing on the signal transduction pathways in the heart that are modulated by anti-erbB2 treatment, which in turn, worsens doxorubicin toxicity. Thus, understanding the mechanisms behind the combined toxicity of doxorubicin and anti-erbB2 will pave the way for the design of strategies to reduce toxicity, identify patients at risk and potentially allow higher levels of this effective combination therapy to be used with an improved long-term survival in patients. view more
Lei Zheng LabLab WebsitePrincipal Investigator:
Lei Zheng, M.D., Ph.D.
Zheng’s research focuses on two R01-funded projects; first, the group has developed a pancreati...c cancer immunotherapy research program on a neoadjuvant therapy platform as well as a number of preclinical models of pancreatic cancer for developing innovative immunotherapy strategies. The group has applied the knowledge gained from pancreatic cancer immune-based therapies to the development of a colorectal cancer GVAX vaccine. Second, the group is aimed at understanding the mechanistic roles of the tumor microenvironment in cancer development and metastasis and identifying new targets for pancreatic cancer therapies by dissecting the tumor microenvironment of pancreatic cancer. view moreResearch Areas: cancer, pancreatic cancer, translational research, tumor microenvironment, immunotherapy